TW200716111A - Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors - Google Patents

Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors

Info

Publication number: TW200716111A
Authority: TW; Taiwan
Prior art keywords: hydroxysteroid dehydrogenase; inhibitors; dehydrogenase type; triazolopyridine; beta
Prior art date: 2005-06-09

Application number

TW095120401A

Other languages

English (en)

Inventor

James J Li

Lawrence G Hamann

hai-xia Wang

Zhe-Ming Ruan

Christopher B Cooper

Jun Li

Jeffrey A Robl

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-09

Filing date

2006-06-08

Publication date

2007-05-01

2006-06-08 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2007-05-01 Publication of TW200716111A publication Critical patent/TW200716111A/zh

Links

102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 title abstract 4
108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 title abstract 4
239000003112 inhibitor Substances 0.000 title abstract 4
OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Pyridine Compounds (AREA)

TW095120401A 2005-06-09 2006-06-08 Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors TW200716111A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US68899305P	2005-06-09	2005-06-09
US11/448,947 US7579360B2 (en)	2005-06-09	2006-06-07	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors

Publications (1)

Publication Number	Publication Date
TW200716111A true TW200716111A (en)	2007-05-01

Family

ID=37574243

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095120401A TW200716111A (en)	2005-06-09	2006-06-08	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors

Country Status (26)

Country	Link
US (2)	US7579360B2 (zh)
EP (1)	EP1888582B1 (zh)
JP (1)	JP4994368B2 (zh)
KR (1)	KR20080019276A (zh)
CN (1)	CN102558176A (zh)
AR (1)	AR054385A1 (zh)
AT (1)	ATE487717T1 (zh)
AU (1)	AU2006257924B2 (zh)
BR (1)	BRPI0611773A2 (zh)
CA (1)	CA2611529C (zh)
CY (1)	CY1111148T1 (zh)
DE (1)	DE602006018135D1 (zh)
DK (1)	DK1888582T3 (zh)
EA (1)	EA013017B1 (zh)
GE (1)	GEP20105073B (zh)
HR (1)	HRP20110073T1 (zh)
IL (1)	IL187812A (zh)
MX (1)	MX2007015285A (zh)
NO (1)	NO20076055L (zh)
NZ (1)	NZ563457A (zh)
PE (1)	PE20070164A1 (zh)
PL (1)	PL1888582T3 (zh)
PT (1)	PT1888582E (zh)
SI (1)	SI1888582T1 (zh)
TW (1)	TW200716111A (zh)
WO (1)	WO2006135795A1 (zh)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0420722D0 (en) *	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
AR059898A1 (es)	2006-03-15	2008-05-07	Janssen Pharmaceutica Nv	Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
JP2010500300A (ja)	2006-08-08	2010-01-07	サノフィ−アベンティス	アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EA017648B1 (ru) *	2007-09-14	2013-02-28	Орто-Макнейл-Янссен Фармасьютикалз, Инк.	1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
TW200922566A (en)	2007-09-14	2009-06-01	Ortho Mcneil Janssen Pharm	1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
BRPI0816970A2 (pt)	2007-09-14	2015-03-24	Ortho Mcneil Janssen Pharm	1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
US8119658B2 (en) *	2007-10-01	2012-02-21	Bristol-Myers Squibb Company	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CA2704436C (en)	2007-11-14	2016-01-05	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2010003624A2 (en)	2008-07-09	2010-01-14	Sanofi-Aventis	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
JP5547194B2 (ja)	2008-09-02	2014-07-09	ジャンセンファーマシューティカルズ，インコーポレイテッド．	代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
WO2010043396A1 (en)	2008-10-16	2010-04-22	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja)	2008-11-28	2015-03-25	ジャンセンファーマシューティカルズ，インコーポレイテッド．	代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EP2417135A1 (en)	2009-04-07	2012-02-15	Schering Corporation	Substituted triazolopyridines and analogs thereof
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (zh)	2009-05-12	2015-05-13	杨森制药有限公司	1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
HRP20131122T1 (hr)	2009-05-12	2013-12-20	Janssen Pharmaceuticals, Inc.	Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
ES2350077B1 (es)	2009-06-04	2011-11-04	Laboratorios Salvat, S.A.	Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
SG178880A1 (en)	2009-08-26	2012-04-27	Sanofi Sa	Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
ES2536433T3 (es)	2010-11-08	2015-05-25	Janssen Pharmaceuticals, Inc.	Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
EP2661435B1 (en)	2010-11-08	2015-08-19	Janssen Pharmaceuticals, Inc.	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JP5852664B2 (ja)	2010-11-08	2016-02-03	ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド	１，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
WO2015061272A1 (en)	2013-10-22	2015-04-30	Bristol-Myers Squibb Company	Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
GB201321742D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
JP2017501145A (ja)	2013-12-23	2017-01-12	ノージンビーブイ	Ｃｃｒ９調節因子として有用な化合物
PL3096790T3 (pl)	2014-01-21	2020-01-31	Janssen Pharmaceutica, N.V.	Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
ME03518B (me)	2014-01-21	2020-04-20	Janssen Pharmaceutica Nv	Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
LT3105218T (lt)	2014-02-13	2019-12-10	Incyte Corp	Ciklopropilaminai kaip lsd1 inhibitoriai
WO2015123424A1 (en)	2014-02-13	2015-08-20	Incyte Corporation	Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (en)	2014-02-13	2018-10-24	Incyte Corporation	Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
WO2016007731A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007736A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Imidazopyrazines as lsd1 inhibitors
US9758523B2 (en)	2014-07-10	2017-09-12	Incyte Corporation	Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007722A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9580420B2 (en)	2014-08-06	2017-02-28	Bristol-Meyers Squibb Company	Process for the preparation of 4-(8-(2-chlorophenoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)bicyclo[2.2.1]heptan-1-ol and novel intermediates therefor
EA201792205A1 (ru)	2015-04-03	2018-02-28	Инсайт Корпорейшн	Гетероциклические соединения как ингибиторы lsd1
DK3334709T3 (da)	2015-08-12	2025-02-03	Incyte Holdings Corp	Salte af en lsd1-hæmmer
CA3021678A1 (en)	2016-04-22	2017-10-26	Incyte Corporation	Formulations of an lsd1 inhibitor
US10689378B2 (en) *	2016-06-20	2020-06-23	Novartis Ag	Triazolopyridine compounds and uses thereof
BR112021002207A2 (pt)	2018-08-10	2021-05-04	Diapin Therapeutics, Llc	tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios
US10968200B2 (en)	2018-08-31	2021-04-06	Incyte Corporation	Salts of an LSD1 inhibitor and processes for preparing the same

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3597423A (en) *	1966-08-31	1971-08-03	Boehringer Mannheim Gmbh	5-nitrofuryl-2-s-triazolo-(4,3-a)-pyridine derivatives
US4358453A (en) *	1982-01-08	1982-11-09	Schering Corporation	1,2,4-Triazolo[4,3-a]pyridines
US5236917A (en) *	1989-05-04	1993-08-17	Sterling Winthrop Inc.	Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
IL96432A0 (en)	1989-11-30	1991-08-16	Schering Ag	Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
WO1997047601A1 (en)	1996-06-11	1997-12-18	Yoshitomi Pharmaceutical Industries, Ltd.	Fused heterocyclic compounds and medicinal uses thereof
EP1175412A1 (en)	1999-04-28	2002-01-30	Dr. Reddy's Research Foundation	Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
JP2000319277A (ja)	1999-05-11	2000-11-21	Ono Pharmaceut Co Ltd	縮合ピラジン化合物およびその化合物を有効成分とする薬剤
JP4747396B2 (ja)	2000-05-17	2011-08-17	日立化成工業株式会社	接着剤組成物、それを用いた回路端子の接続方法及び回路端子の接続構造
OA12552A (en) *	2001-03-09	2006-06-06	Pfizer Prod Inc	Triazolopyridines as anti-inflammatory agents.
US20050113283A1 (en) *	2002-01-18	2005-05-26	David Solow-Cordero	Methods of treating conditions associated with an EDG-4 receptor
WO2003065983A2 (en)	2002-02-01	2003-08-14	Merck & Co., Inc.	11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es)	2002-06-10	2005-03-23	Merck & Co Inc	Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
JP2006508914A (ja) *	2002-08-30	2006-03-16	ファイザー・プロダクツ・インク	トリアゾロ−ピリジン製造のための新規な方法および中間体
MY139563A (en) *	2002-09-04	2009-10-30	Bristol Myers Squibb Co	Heterocyclic aromatic compounds useful as growth hormone secretagogues
JO2397B1 (en)	2002-12-20	2007-06-17	ميرك شارب اند دوم كوربوريشن	Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004056744A1 (en)	2002-12-23	2004-07-08	Janssen Pharmaceutica N.V.	Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
TW200503994A (en)	2003-01-24	2005-02-01	Novartis Ag	Organic compounds
EP1601672B1 (en) *	2003-02-14	2006-07-26	Pfizer Products Inc.	Triazolo-pyridines as anti-inflammatory compounds
ATE455547T1 (de)	2003-04-11	2010-02-15	High Point Pharmaceuticals Llc	Pharmazeutische verwendungen von kondensierten 1, 2,4-triazolen
EP1619948A4 (en) *	2003-05-05	2007-02-14	Neurogen Corp	SUBSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS
ATE476425T1 (de)	2003-05-29	2010-08-15	Merck Sharp & Dohme	Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1
US20050049276A1 (en) *	2003-07-23	2005-03-03	Warner-Lambert Company, Llc	Imidazopyridines and triazolopyridines
US7538120B2 (en) *	2003-09-03	2009-05-26	Array Biopharma Inc.	Method of treating inflammatory diseases
US7144907B2 (en) *	2003-09-03	2006-12-05	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
GB0325745D0 (en)	2003-11-05	2003-12-10	Astrazeneca Ab	Chemical compounds
GB0326029D0 (en)	2003-11-07	2003-12-10	Astrazeneca Ab	Chemical compounds
CA2553345C (en)	2004-01-26	2011-11-15	Merck & Co., Inc.	Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
US7306631B2 (en) *	2004-03-30	2007-12-11	The Procter & Gamble Company	Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
DE502005003491D1 (de)	2004-08-02	2008-05-08	Sanol Arznei Schwarz Gmbh	Carboxamide des indolizins und seiner aza- und diazaderivate
AU2005273612B2 (en) *	2004-08-12	2010-10-14	Pfizer Inc.	Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
MX2007002050A (es)	2004-08-18	2007-03-29	Pharmacia & Upjohn Co Llc	Compuestos de triazolopiridina.
JP2008509985A (ja)	2004-08-18	2008-04-03	ファルマシアアンドアップジョンカンパニーリミテッドライアビリティカンパニー	炎症治療用の新規トリアゾロピリジン化合物
CN101048407A (zh)	2004-09-03	2007-10-03	普莱希科公司	双环杂芳基pde4b抑制剂
CN101014578B (zh)	2004-09-16	2011-01-19	安斯泰来制药有限公司	三唑衍生物或其盐
WO2006036816A2 (en)	2004-09-24	2006-04-06	Smithkline Beecham Corporation	Chemical compounds
CN101039942A (zh)	2004-09-27	2007-09-19	伊利舍医药品公司	磺酰胺类及其用途
BRPI0515931A (pt)	2004-09-29	2008-08-12	Hoffmann La Roche	compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
EP1799680A2 (en)	2004-10-07	2007-06-27	Warner-Lambert Company LLC	Triazolopyridine derivatives as antibacterial agents
JPWO2006038738A1 (ja)	2004-10-08	2008-05-15	武田薬品工業株式会社	受容体機能調節剤
ES2365858T3 (es)	2004-10-13	2011-10-11	Merck Patent Gmbh	Derivados de fenilurea como sustancia inhibidora de tirosina-quinasas para el tratamiento de enfermedades tumorales.
JP5065034B2 (ja)	2004-10-13	2012-10-31	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	キナーゼ阻害剤として適しているｎ，ｎ’−ジフェニル尿素誘導体
EP1812439B2 (en)	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinase inhibitors
GB0519957D0 (en)	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
US7652035B2 (en)	2004-10-19	2010-01-26	Neurocrine Bioscience, Inc.	CRF receptor antagonists and methods relating thereto
US7151176B2 (en)	2004-10-21	2006-12-19	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
CA2588350A1 (en)	2004-10-25	2006-05-04	University Of Medicine And Dentistry Of New Jersey	Anti-mitotic anti-proliferative compounds
WO2006049952A1 (en)	2004-10-29	2006-05-11	Eli Lilly And Company	Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP1655283A1 (en)	2004-11-08	2006-05-10	Evotec OAI AG	11beta-HSD1 Inhibitors
EP1666467A1 (en)	2004-11-08	2006-06-07	Evotec AG	11Beta-HSD1 Inhibitors
ES2330872T3 (es)	2004-12-01	2009-12-16	Merck Serono Sa	Derivados de (1,2,4)triazolo(4,3-a)piridina para el tratamiento de enfermedades hiperproliferativas.
JPWO2006080533A1 (ja)	2005-01-31	2008-06-19	持田製薬株式会社	３−アミノ−１，２，４−トリアゾール誘導体
WO2007007688A1 (ja)	2005-07-08	2007-01-18	Mochida Pharmaceutical Co., Ltd.	３,５－ジアミノ－１,２,４－トリアゾール誘導体
JP2009531390A (ja)	2006-03-31	2009-09-03	ノバルティスアクチエンゲゼルシャフト	有機化合物

2006
- 2006-06-07 US US11/448,947 patent/US7579360B2/en active Active
- 2006-06-08 TW TW095120401A patent/TW200716111A/zh unknown
- 2006-06-08 NZ NZ563457A patent/NZ563457A/en not_active IP Right Cessation
- 2006-06-08 EP EP06784721A patent/EP1888582B1/en not_active Expired - Lifetime
- 2006-06-08 BR BRPI0611773-2A patent/BRPI0611773A2/pt not_active IP Right Cessation
- 2006-06-08 DE DE602006018135T patent/DE602006018135D1/de not_active Expired - Lifetime
- 2006-06-08 DK DK06784721.0T patent/DK1888582T3/da active
- 2006-06-08 CN CN2011104026933A patent/CN102558176A/zh active Pending
- 2006-06-08 AU AU2006257924A patent/AU2006257924B2/en not_active Ceased
- 2006-06-08 WO PCT/US2006/022576 patent/WO2006135795A1/en not_active Ceased
- 2006-06-08 EA EA200800006A patent/EA013017B1/ru not_active IP Right Cessation
- 2006-06-08 KR KR1020087000469A patent/KR20080019276A/ko not_active Ceased
- 2006-06-08 PE PE2006000636A patent/PE20070164A1/es not_active Application Discontinuation
- 2006-06-08 JP JP2008515986A patent/JP4994368B2/ja not_active Expired - Fee Related
- 2006-06-08 GE GEAP200610470A patent/GEP20105073B/en unknown
- 2006-06-08 MX MX2007015285A patent/MX2007015285A/es active IP Right Grant
- 2006-06-08 AR ARP060102406A patent/AR054385A1/es unknown
- 2006-06-08 AT AT06784721T patent/ATE487717T1/de active
- 2006-06-08 PT PT06784721T patent/PT1888582E/pt unknown
- 2006-06-08 CA CA2611529A patent/CA2611529C/en not_active Expired - Fee Related
- 2006-06-08 PL PL06784721T patent/PL1888582T3/pl unknown
- 2006-06-08 SI SI200630920T patent/SI1888582T1/sl unknown
- 2006-06-08 HR HR20110073T patent/HRP20110073T1/hr unknown
2007
- 2007-11-26 NO NO20076055A patent/NO20076055L/no not_active Application Discontinuation
- 2007-12-02 IL IL187812A patent/IL187812A/en not_active IP Right Cessation
2009
- 2009-04-16 US US12/424,674 patent/US8148396B2/en active Active
2011
- 2011-01-31 CY CY20111100103T patent/CY1111148T1/el unknown

Also Published As

Publication number	Publication date
US7579360B2 (en)	2009-08-25
CY1111148T1 (el)	2015-06-11
CN102558176A (zh)	2012-07-11
PL1888582T3 (pl)	2011-05-31
IL187812A0 (en)	2008-08-07
WO2006135795A1 (en)	2006-12-21
AR054385A1 (es)	2007-06-20
HK1112463A1 (zh)	2008-09-05
KR20080019276A (ko)	2008-03-03
EA013017B1 (ru)	2010-02-26
NZ563457A (en)	2010-06-25
US20090203668A1 (en)	2009-08-13
ATE487717T1 (de)	2010-11-15
NO20076055L (no)	2008-03-05
PT1888582E (pt)	2011-01-14
BRPI0611773A2 (pt)	2010-09-28
US20060287357A1 (en)	2006-12-21
AU2006257924A1 (en)	2006-12-21
DE602006018135D1 (de)	2010-12-23
PE20070164A1 (es)	2007-03-11
EP1888582B1 (en)	2010-11-10
CA2611529C (en)	2013-12-03
IL187812A (en)	2012-02-29
AU2006257924B2 (en)	2012-03-08
EP1888582A1 (en)	2008-02-20
MX2007015285A (es)	2008-02-22
JP4994368B2 (ja)	2012-08-08
US8148396B2 (en)	2012-04-03
CA2611529A1 (en)	2006-12-21
SI1888582T1 (sl)	2011-03-31
JP2008543776A (ja)	2008-12-04
EA200800006A1 (ru)	2008-06-30
GEP20105073B (en)	2010-09-10
HRP20110073T1 (hr)	2011-02-28
DK1888582T3 (da)	2011-02-28

Publication	Publication Date	Title
MX2010003565A (es)	2010-04-21	Inhibidores de 11-beta hidroxiesteroide deshidrogenasa tipo i de triazolopiridina.
TW200716116A (en)	2007-05-01	Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2006113261A3 (en)	2006-11-30	Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
WO2007103694A3 (en)	2007-11-01	Triazine 11-beta hydroxysteroid dehydrogenase type i inhibitors
EA200800006A1 (ru)	2008-06-30	Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
WO2008024892A3 (en)	2008-12-11	Cyclic 11-beta hydroxysteroid dehydrogenase type i inhibitors
MY146111A (en)	2012-06-29	Acylaminopyrazoles as fgfr inhibitors
WO2008147864A3 (en)	2009-07-09	Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
GEP20084421B (en)	2008-07-10	Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
MX2009003157A (es)	2009-04-03	Pirazoliltienopiridinas terapeuticas.
MX2010002732A (es)	2010-06-02	Inhibidores de f1f0-atpasa y metodos relacionados.
MX2009009290A (es)	2009-09-10	Compuestos activos en ppar.
WO2006028958A3 (en)	2006-04-13	Pyridyl inhibitors of hedgehog signalling
TW200718689A (en)	2007-05-16	2-Amino-quinazolin-5-ones
ZA200810113B (en)	2010-02-24	Method for the treatment and prevention of ocular disorders
MX2009012705A (es)	2009-12-08	Combinacion de inhibidores de cinasa de control y poli(adp-ribosa)polimerasa-1 para el tratamiento de canceres.
IL189694A0 (en)	2008-06-05	Biphenyl derivatives and their use in treating hepatitis c
PL1771178T3 (pl)	2010-01-29	Zastosowanie K-252A i inhibitorów kinazy do zapobiegania lub leczenia patologii związanych z HMGB1
MX2008011633A (es)	2008-12-16	Aminoquinolonas como inhibidores de gsk-3.
WO2007112014A3 (en)	2007-12-21	New therapeutic combinations for the treatment of depression
MY145795A (en)	2012-04-30	Pyrazoline compounds
NZ596000A (en)	2013-10-25	Carboxamide compounds and their use as calpain inhibitors
TW200736229A (en)	2007-10-01	Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
MY140514A (en)	2009-12-31	Triazolopyridine derivatives as inhibitors of lipases and phospholipases
IL219644A0 (en)	2012-06-28	Kinase inhibitors and methods of use thereof